0
Original Research: PULMONARY REHABILITATION |

Effects of Pulmonary Rehabilitation in Patients With Restrictive Lung Diseases

Bihiyga Salhi, PT; Thierry Troosters, PT, PhD; Mia Behaegel, MD; Guy Joos, MD, PhD; Eric Derom, MD, PhD
Author and Funding Information

From the Department of Respiratory Medicine (Ms Salhi, Drs Behaegel, Joos, and Derom), Ghent University Hospital, Ghent; the Respiratory Rehabilitation and Respiratory Division (Dr Troosters), University Hospitals, Leuven, and the Faculty of Kinesiology and Rehabilitation Sciences (Dr Troosters), Katholieke Universiteit Leuven, Leuven, Belgium.

Correspondence to: Bihiyga Salhi, PT, Department of Respiratory Medicine, Ghent University Hospital, 7K12, IE, De Pintelaan, 185, B-9000 Ghent, Belgium; e-mail: Bihiyga.Salhi@UGent.be


For editorial comment see page 247

Funding/Support: The REVALIS study was supported by the National Institute for Health and Disability Insurance (NIHDI). Dr Troosters is a postdoctoral fellow of the FWO-Vlaanderen.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml).


© 2010 American College of Chest Physicians


Chest. 2010;137(2):273-279. doi:10.1378/chest.09-0241
Text Size: A A A
Published online

Background:  Pulmonary rehabilitation programs improve exercise tolerance, muscle strength, and dyspnea in patients with COPD. The aim of the study was to assess prospectively the effectiveness and feasibility of pulmonary rehabilitation in patients with restrictive lung diseases.

Methods:  In a prospective, nonrandomized, noncontrolled study, patients with an established diagnosis of restrictive lung disease (RLD) participated in a 24-week outpatient multidisciplinary rehabilitation program. Pulmonary function, exercise capacity, muscle force, and dyspnea were measured at inclusion, after 12 and 24 weeks of rehabilitation. Primary outcome was the change in 6-min walk distance (6MWD) after 12 weeks of rehabilitation.

Results:  Twenty-nine patients out of 31 patients (57 ± 17 years of age; 21 men; FEV1: 1.4 ± 0.7 L) completed the 12-week rehabilitation program and 26 patients the 24-week rehabilitation program. At inclusion, exercise tolerance (maximal oxygen consumption [Vo2max]: 63% ± 27% predicted; 6MWD: 390 ± 140 m) and quadriceps force ([QF] 61% ± 21% predicted) were reduced, and dyspnea, assessed using the Chronic Respiratory Disease Questionnaire (CRDQ), was increased (CRDQ item dyspnea [CRDQd]: 16 ± 6 points). Exercise capacity, muscle force, and CRDQd improved significantly after 12 weeks (6MWD: 445 ± 142 m; VO2max: 69% ± 30% predicted; QF: 73% ± 25% predicted; CRDQd: 20 ± 6 points) (P < .05). Further improvements were noted after 24 weeks (6MWD: 463 ± 146 m; CRDQd: 22 ± 6 points).

Conclusions:  Patients with RLD respond well after 12 weeks of pulmonary rehabilitation, and even better results were seen after 24 weeks. Clinically significant improvements were obtained in the majority of the patients after 24 weeks.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543